Hormone replacement therapy" was originally reported by Murray, who
in 1891 described the successful treatment of myxedema with injections of
sheep thyroid extract.1 By 1898, therapy for
this chronic, severely debilitating condition was hailed as "unparalleled
by anything in the whole range of curative measures" by Osler.2 Seven
decades later, desiccated thyroid was characterized by the standard thyroid
textbook of the day as ". . . as perfect a form of therapy as any known to
medicine. . . ."3 With the subsequent identification
of thyroxine (T4) and triiodothyronine (T3) as the 2
major thyroid hormones, it was assumed that replacement therapies containing
both compounds were more physiological than treatment with either alone. Thus,
despite the availability of synthetic T4 in the early 1960s, the
prescription of desiccated animal thyroid or synthetic combinations of T4 and T3 continued well into the 1970s.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 19
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
The Rational Clinical Examination
Population for Whom a Goiter Disease Should Be Considered
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.